Leerink Partners Initiates Coverage On Parabilis Medicines with Outperform Rating, Announces Price Target of $40

Benzinga Newsdesk www.benzinga.com Positive 69.3%

Neg 0% Neu 0% Pos 69.3%

Leerink Partners analyst Andrew Berens initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Outperform rating and announces Price Target of $40.